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Background: Cigarette smoking causes Chronic Obstructive Pulmonary Disease (COPD), the 3rd leading cause of
death in the U.S. CFTR ion transport dysfunction has been implicated in COPD pathogenesis, and is associated with
chronic bronchitis. However, susceptibility to smoke induced lung injury is variable and the underlying genetic
contributors remain unclear. We hypothesized that presence of CFTR mutation heterozygosity may alter
susceptibility to cigarette smoke induced CFTR dysfunction. Consequently, COPD patients with chronic bronchitis
may have a higher rate of CFTR mutations compared to the general population.
Methods: Primary human bronchial epithelial cells derived from F508del CFTR heterozygotes and mice with
(CFTR+/−) and without (CFTR+/+) CFTR heterozygosity were exposed to whole cigarette smoke (WCS); CFTR-dependent
ion transport was assessed by Ussing chamber electrophysiology and nasal potential difference measurements,
respectively. Caucasians with COPD and chronic bronchitis, age 40 to 80 with FEV1/FVC < 0.70 and FEV1 < 60%
predicted, were selected for genetic analysis from participants in the NIH COPD Clinical Research Network’s
Azithromycin for Prevention of Exacerbations of COPD in comparison to 32,900 Caucasian women who underwent
prenatal genetic testing. Genetic analysis involved an allele-specific genotyping of 89 CFTR mutations.
Results: Exposure to WCS caused a pronounced reduction in CFTR activity in both CFTR (+/+) cells and F508del
CFTR (+/−) cells; however, neither the degree of decrement (44.7% wild-type vs. 53.5% F508del heterozygous,
P = NS) nor the residual CFTR activity were altered by CFTR heterozygosity. Similarly, WCS caused a marked
reduction in CFTR activity measured by NPD in both wild type and CFTR heterozygous mice, but the severity of
decrement (91.1% wild type vs. 47.7% CF heterozygous, P = NS) and the residual activity were not significantly
affected by CFTR genetic status. Five of 127 (3.9%) COPD patients with chronic bronchitis were heterozygous for
CFTR mutations which was not significantly different from controls (4.5%) (P = NS).
Conclusions: The magnitude of WCS induced reductions in CFTR activity was not affected by the presence of CFTR
mutation heterozygosity. CFTR mutations do not increase the risk of COPD with chronic bronchitis. CFTR dysfunction due
to smoking is primarily an acquired phenomenon and is not affected by the presence of congenital CFTR mutations.Introduction
Chronic obstructive pulmonary disease (COPD) is the
3rd leading cause of death in the U.S. and mortality is
increasing [1]. An improved understanding of COPD
pathogenesis, and the genes that contribute to its pro-
gression, are needed to develop therapeutic approaches* Correspondence: smrowe@uab.edu
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stated.to the disease [2]. Susceptibility to lung injury from
cigarette smoking is highly variable, with only ~15-20%
of at risk individuals developing clinically significant
COPD. While the presence of the Z allele of the alpha-
1-antitrypsin (AAT) gene has been shown to increase
the risk for COPD [3,4], it only accounts for a small
fraction of cases. GWAS studies have not yet identified
genetic contributors with a firm link to disease patho-
genesis [5,6]. Complicating this further is the fact that
the phenotypic expression of COPD is highly variable,
with some individuals developing disease dominated by
emphysema while others exhibit chronic bronchitis or. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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tiple pathologic mechanisms.
There are more than 10 million Americans who are
asymptomatic carriers of at least one CFTR mutation
[9]. A number of disorders are associated with mild/vari-
able CFTR mutations that cause intermediate pheno-
typic expression. For example, 30-50% of patients with
idiopathic pancreatitis are heterozygotes for CFTR muta-
tions [10,11], and a similar association has been made
for congenital bilateral absence of the vas deferens [12]
and allergic pulmonary aspergillosis [13]. We have previ-
ously reported that smokers with COPD have decreased
CFTR function in both the upper [14] and lower airways
[15], confirming prior studies in healthy smokers [16,17]
and suggesting that CFTR dysfunction may also play a
role in the pathogenesis of COPD. CFTR dysfunction
was also found to be associated with chronic bronchitis
symptoms and dyspnea [14,15], indicating CFTR abnor-
mality may be particularly important towards causing
mucus retention, and supports in vitro studies indicating
reduced airway surface liquid depth [14,17] and delayed
mucociliary transport [14,18] caused by cigarette smoke
exposure. CFTR dysfunction has also been observed in
mice exposed to whole cigarette smoke [19]. Since, a
surprisingly large percentage of COPD patients have re-
cently been found to have bronchiectasis by high reso-
lution CT [20] and because chronic bronchitis shares
many pathologic similarities with CF, it follows that gen-
etic CFTR abnormalities may increase the prevalence of
chronic bronchitis in smokers.
A previous study identified a moderate association be-
tween F508del CFTR mutations and in individuals with
chronic bronchitis and sweat chloride levels of 60 mmol/L
or higher [21]. Other studies demonstrating an association
have been small and have not examined the frequency of
CFTR mutations in COPD subtypes [22-24]. An associ-
ation between common CFTR mutations and chronic
bronchitis was not observed by Entzian et al. [25]. Simi-
larly, earlier studies from Germany and Japan failed to
detect an association between CFTR mutations and
COPD [26,27], although neither focused on individuals
with chronic bronchitis.
In this study, we hypothesized CFTR mutation hetero-
zygosity would increase the susceptibility to cigarette smoke
induced CFTR dysfunction. To our surprise, in vitro and
in vivo studies revealed an absence of a gene-dose effect
between cigarette smoking and CFTR dysfunction. This
was further supported by the absence of increased CFTR
mutation frequency in chronic bronchitis patients when
compared to the general population. These findings indi-
cate that CFTR dysfunction due to smoking is primarily
an acquired phenomenon, and that CFTR mutations do
not significantly increase the prevalence of acquired
CFTR dysfunction induced chronic bronchitis.Methods
In vitro experiments with primary human airway
epithelial cells
UAB Institutional Review Board approved the use of
human cells. Primary human bronchial epithelial cells
(HBE) were obtained from lung explants. Genetic analysis
was performed to identify cells with expression of wild type
CFTR (CFTR +/+) and those heterozygous for non-
functional (i.e. F508del) CFTR mutations (CFTR +/−)
following previously described methods [28]. After
expanding isolated HBE cells, first or second passage
cells were seeded on permeable support filters (Corning,
Lowell, MA) coated with NIH 3 T3 fibroblast condi-
tioned media. HBE cells were grown in differentiating
media for 6 weeks until terminally differentiated, as
previously described [14].
HBE cells were exposed to WCS from one 3R4F re-
search cigarette (University of Kentucky, Lexington,
KY) for 10 min. WCS was generated via an automated
cigarette smoke generator (Scireq InExpose model,
Toronto, Canada) at 1 puff/min at a flow rate of 3 L/min,
as previously described [19]. Controls cells were similarly
exposed to room air.
CFTR-dependent short circuit current was measured
in Ussing chambers under voltage clamp conditions
using MC8 voltage clamps and P2300 Ussing chambers
(Physiologic Instruments, San Diego, CA) [14]. CFTR
activity was measured by the change in Isc upon stimu-
lation with forskolin (10 μM) in the setting of amiloride
(100 μM). A Cl- secretory gradient was used, where indi-
cated; CFTRInh-172 (10 μM) was used to confirm CFTR
dependence [29].
In vivo cigarette smoke exposure
Animal protocols were approved by the UAB Institu-
tional Animal Care and Use Committee. Age and sex
matched congenic C57BL/6 J mice expressing wild type
CFTR (CFTR +/+) or heterozygous for CFTR knock out
(CFTR +/−, C57BL/6 J Cftrtm1Unc/J) were used. Mice
were exposed in whole-body chambers (28″ × 19″ ×
15″) to mainstream cigarette smoke (200 μg/l of total
particulate matter, 35-ml puffs of 2-s duration at a rate
of 3 L/sec each minute for 20 min) from 4 3R4F refe-
rence cigarettes (Univ. of Kentucky, Lexington, KY)
twice daily for 2 weeks using an automated cigarette
smoking apparatus (SCIREQ, InExpose model, Toronto,
Canada). Control mice were exposed to room air under
similar conditions [19,30].
Measurement of murine CFTR activity
Murine CFTR function was assessed by nasal potential dif-
ference measurements. Under anesthesia, CFTR-dependent
anion transport was measured in the murine nasal epithe-
lium as a change in potential difference following perfusion
Table 1 List of CFTR mutations analyzed
F508del R117H 1717-1G > A R117C
G85E R334W 1898 + 1G > A Y122X
A455E R347P 2184delA G178R
I507del R553X 2789 + 5G > A G314E
G542X R560T 3120 + 1G > A G330X
G551D W1282X 3659delC R347H
N1303K 621 + 1G > T K710X 406-1G > A
R1162X 711 + 1G > T E60X G480C
R1066C W1089X V520F A559T
S1196X Q1238X S1251N S1255X
663delT 935delA 1161delC 1288insTA
2184insA 2307insA 2711delT 2869insG
R709X R764X R1158X 574delA
Q493X 1898 + 5G > T 3905insT I506T
3849 + 10kbC > T 712-1G > T Q98R Q552X
S549N 1078delT H199Y 444delA
S549R (T > G) 2143delT P205S 2043delG
1811 + 1.6kbA > G 3272-26A > G L206W 3791delC
Y1092X (C > G) 3199del6 F508C 2108delA
Y1092X (C > A) D1152H V520I 3667del4
394delTT 3876delA M1101K 1677delTA
W1098X (TGA) 1812-1G > A 4016insT 1609delCA
3171delC
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amiloride (100 μM), as previously described [19,29].
Mice were euthanized and tracheas were harvested by
clean surgical techniques. Tracheal epithelia were mounted
and tested as full-thickness tissue. Isc was measured under
voltage clamp conditions as performed in cells using
P2307 Ussing chamber sliders. Mounted tissues were
bathed on both sides with identical Ringers solutions
gassed with 95% O2:5% CO2 and then treated with amilor-
ide (100 μM) followed by the CFTR agonists forskolin
(10 μM) and IBMX (100 μM); bumetanide (10 μM) and
glybenclamide (100 μM) were added to the mucosal solu-
tion at the end of experiments to block CFTR-dependent
Isc. Results are expressed as the change in Isc with agonist
stimulation [19,31].
Genetic analysis of chronic bronchitis
We performed a case control study to detect the preva-
lence of CFTR mutations in COPD patients with symp-
toms of chronic bronchitis. The UAB IRB approved use
of clinical specimens for the research study. COPD cases
were selected from participants in the NIH COPD Clin-
ical Research Network’s Azithormycin in COPD Study
who had blood stored for genetic analysis [32]. Cases
were non-Hispanic Caucasians, age 40 to 80 with FEV1/
FVC < 0.70 and FEV1 < 60% predicted, and chronic bron-
chitis defined by productive cough “most days a week”
or “several days of the week” on the St. George Respira-
tory Questionnaire (SGRQ). The control population was
32,900 Caucasian women who had CFTR analyzed for
prenatal genetic testing, N = 32,900. No further demo-
graphic characteristics are available for this population.
DNA testing was performed by the Baylor College of
Medicine Genetics Laboratory using a CFTR related dis-
orders mutation panel. This is an allele-specific genotyp-
ing technique for 89 mutations (Table 1) performed by
MALDI-TOF mass spectrometry and includes testing
for mutations common in human populations and reflex
testing of the 5 T allele. The method has an 88% CFTR
mutation detection rate in the non-Hispanic Caucasian
population. Additional data collected on COPD cases in-
cluded age, sex, smoking status, smoking intensity (pack-
years), FEV1% predicted, and the number of COPD exac-
erbations requiring treatment in the year prior to enroll-
ment in the azithromycin trial. The sample size of 127
patients had 80% power to detect a mutation rate in
COPD patients of 10.5% as compared to a presumed fre-
quency of 4.5% in controls with an alpha of 0.05.
Statistics
For in vitro and in vivo studies, descriptive statistics
(mean, SD, and SEM) were compared using Student’s
t-test or ANOVA, as appropriate. Post-hoc tests for
multiple comparisons were calculated using Fisher’sleast significant difference. Population statistics were
performed using SAS (IBM, Armonk, NY). Chi-square
or Fischer’s exact test used for inferential comparisons.
All statistical tests were two-sided and were performed
at a 5% significance level (i.e., α = 0.05) using Graph-
Pad Prism (La Jolla, CA). Error bars designate SEM
unless indicated otherwise.
Results
Effect of CFTR mutation heterozygosity on smoke-
induced CFTR dysfunction in vitro
Since smokers with and without COPD exhibit reduced
CFTR mediated anion transport [14-17,19], and this is
associated with chronic bronchitis [14,15,19], we hypoth-
esized that acquired CFTR dysfunction may also be in-
fluenced by the presence of congenital CFTR mutations.
As a test of this hypothesis, we exposed primary HBE
cells heterozygous for the F508del CFTR mutation to
whole cigarette smoke and compared this to the degree
of CFTR decrement observed in HBE cells without
CFTR mutations (e.g. wild-type expressing monolayers).
As expected based on genotype-phenotype correlations
in the disease [33], HBE cells derived from a F508del
CFTR heterozygote had slightly lower CFTR activity at
baseline than wild type monolayers as measured by
Raju et al. Respiratory Research 2014, 15:18 Page 4 of 9
http://respiratory-research.com/content/15/1/18response to forskolin stimulation (49.3 ± 11.5 μA/cm2 in
CFTR (+/+) vs. 40.5 ± 5.3 μA/cm2 in CFTR (+/−), al-
though this was not statistically significant (Figure 1A,B).
WCS caused a pronounced reduction (27.3 ± 3.1 μA/cm2)
in CFTR activity in CFTR (+/+) monolayers (P < 0.05),
consistent with prior studies using WCS [17,19,30,34,35]
and CSE [14,36]. WCS also caused a significant decrement
in CFTR (+/−) cells (18.8 ± 2.4 μA/cm2; P < 0.005). Both
the relative decrement (44.7% vs. 53.5%, P < 0.93) and the
degree of residual CFTR activity in CFTR (+/+) and CFTR
(+/−) cells following WCS exposure (22.1 ± 3.0 μA/cm2 in
CFTR +/+ vs. 21.6 ± 3.8 μA/cm2 in CFTR +/−) was indis-
tinguishable, indicating the presence of a single F508del
CFTR mutation did not meaningfully alter the CFTR dec-
rement from environmental exposure to WCS in vitro.
Effect of CFTR mutation heterozygosity on smoke-
induced CFTR dysfunction in vivo
To better understand findings in human bronchial epithe-
lial cells and provide definitive evidence regarding the
contribution of heterozygous CFTR mutations to cigaretteA
B
Figure 1 Effect of CFTR mutation heterozygosity on smoke-induced C
bronchial epithelial cells (HBE) cells were isolated from healthy non-smoker
(CFTR +/+) or heterozygous F508del CFTR mutation (CFTR +/−). These cells
10 min and CFTR function measured in Ussing chambers under voltage cla
CFTR ion transport in HBE cells in vitro. Addition of forskolin (20 μM) and CFTR
anion transport is summarized, N = 6-8 *P < 0.05, **P < 0.005.smoke induced CFTR dysfunction, we next used an ani-
mal model of cigarette smoke exposure. Congenic wild
type (CFTR +/+) and heterozygote (CFTR +/−, C57BL/6 J
Cftrtm1Unc/J) CF57BL/6 J mice were exposed in whole
body chambers to cigarette smoke twice daily for 2 weeks,
and then CFTR activity was measured in the respiratory
tract by nasal potential difference (NPD) and short circuit
current analysis of freshly excised trachea. As expected
based on genotype-phenotype correlations in the dis-
ease, and observed in prior NPD studies in humans
[33], NPD in heterozygote CFTR (+/−) mice had
slightly lower CFTR activity when compared to the wild
type mice (−12.1 ± 1.8 mV in CFTR (+/+) vs. -8.7 ±
0.6 mV in CFTR (+/−)), although this was not statisti-
cally significant (P < 0.14, Figure 2). Cigarette smoke ex-
posure caused a significant decrease in CFTR-mediated
ion transport in the nasal airway that was similar in se-
verity to the observations in HBE cells (Figure 2). WCS
caused a pronounced reduction (−11.1 mV) in CFTR
activity in CFTR (+/+) mice (P < 0.005), a finding reca-
pitulated in CFTR (+/−) mice (−4.1 mV; P < 0.05).FTR dysfunction in vitro. Well differentiated primary human
s and non-CF individuals and expressing either wild type CFTR
were exposed to cigarette smoke generated from 1 cigarette for
mp conditions. A) Representative tracings of forskolin stimulated
inh172 (10 μM) are indicated. B) Forskolin-stimulated CFTR-dependent
AB
Figure 2 Effect of CFTR mutation heterozygosity on smoke-induced CFTR dysfunction in vivo. C57BL/6 J mice expressing wild type CFTR
(CFTR +/+) or heterozygous CFTR (CFTR +/−) were exposed to whole cigarette smoke (4 cigarettes, twice daily) or room air control in whole
body chambers for 2 weeks prior to CFTR functional estimation with nasal potential difference (NPD). A) Representative tracings of NPD
measured in CFTR +/+ or CFTR +/− mice exposed to either cigarette smoke or air control. Initiation of amiloride (100 μM), Cl- free ringers and
Cl- free ringers plus forskolin (20 μM) are indicated. B) Mean forskolin stimulated change in nasal potential difference, an indicator of CFTR
mediated cl- transport. N = 8/condition, *P < 0.05, **P < 0.005.
Figure 3 Effect of CFTR mutation heterozygosity on smoke-
induced CFTR dysfunction in murine trachea. C57BL/6 J mice
expressing wild type CFTR (CFTR +/+) or heterozygous CFTR knockout
(CFTR +/−) were exposed to whole cigarette smoke (4 cigarettes, twice
daily) or room air control in whole body chambers for 2 weeks prior
to CFTR functional estimation in trachea ex-vivo by Ussing chamber
electrophysiology. CFTR activity was estimated as cAMP-dependent
change in tracheal short circuit current (Isc) by stimulating with forskolin
(20 μM) plus IBMX (100 μM). N = 8/condition, ϕ = 0.25 and, γ= 0.08.
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prominent in heterozygous mice, the residual cAMP
dependent CFTR activity in CFTR (+/+) and CFTR (+/−)
mice following WCS exposure were no different and fa-
vored heterozygous animals (−0.99 ± 2.07 mV in CFTR
(+/+) vs. -4.57 ± 2.05 mV in CFTR (+/−), P = 0.26). Ana-
lysis of short-circuit current of excised trachea demon-
strated a similar trend, with reduced CFTR dependent ion
transport observed in both wild type and heterozygous
trachea following WCS exposure that was not meaning-
fully different (Figure 3). The lack of statistically significant
reduction in trachea CFTR activity following a 2-week ex-
posure to WCS is consistent with previously reported data
since this tissue exhibits time-dependent decrements [19].
Taken together, these data provide evidence that heterozy-
gosity imposed by the presence of one CFTR mutation
does not increase the susceptibility or magnitude of CFTR
dysfunction following cigarette smoke exposure.
Prevalence of CFTR mutations in patients with COPD and
chronic bronchitis
The lack of the expected increase in susceptibility to
cigarette smoke induced CFTR dysfunction due to the
Table 3 Prevalence of CFTR mutations in Caucasian COPD
and control subjects
Study population With mutation Without mutation P Value
COPD N = 127
Any mutation 5 (3.9%) 122 (96.1%) 0.92
F508del 2 (1.5%) 125 (98.5%) 0.63
Non-F508del 3 (2.4%) 124 (97.6%) 0.63
Controls N = 32,900
Any mutation 1,356 (4.1%) 31,544 (95.9%)
F508del 880 (2.7%) 32,020 (97.3%)
Non-F508del 476 (1.4%) 32,424 (98.6%)
P-values presented are Chi-square analyses compared to general Caucasian
population.
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the prevalence of CFTR mutations among COPD pa-
tients with chronic bronchitis in comparison to the gen-
eral Caucasian population. We evaluated 127 individuals
with COPD and chronic bronchitis who participated in
the Azithromycin in COPD Study sponsored by the
COPD Clinical Research Network [37]. To enrich the
population for those likely to exhibit CFTR abnormality,
and assure best matching with our control group, we re-
stricted the analysis to individuals with COPD, chronic
bronchitis and of Caucasian descent. As shown in
Table 2, the population had a slight male predominance,
and 25% were current smokers. The mean FEV1% pre-
dicted reflected a moderate to severely ill population.
There was a high frequency of health care utilization for
respiratory symptoms and pulmonary exacerbations. Five
of the 127 subjects (3.9%) had detectable CFTR muta-
tions based on a genetic panel containing 89 mutations.
The frequency of CFTR mutations among those with
COPD and chronic bronchitis was no different than the
mutation rate seen in the control population (1356 of
32900, 4.1%; P = NS; Table 3). Limiting the analysis to
the F508del CFTR mutation, only 2 (1.5%) of cases were
positive, which was again no different than controls
(2.7%; P = NS).
Discussion
A number of studies have shown that cigarette smoke
causes acquired CFTR dysfunction in smokers with and
without COPD [14,15,17,19,30,38]. Here, we evaluated
the effect CFTR heterozygosity on this pathway using
in vitro and in vivo models of smoke exposure. As ex-
pected, cigarette smoke exposure reduced CFTR func-
tion in mice and cells, consistent with prior literature
[25,26]. However, CFTR heterozygosity did not cause a
functional disadvantage in either mice or primary human
epithelia. At baseline mice and cells with CFTR (+/−) ex-
pression had slightly lower ion transport functionTable 2 Characteristics of COPD study subjects




Current smokers (%) 25
Average pack/years 64
Hospitalizations or emergency department visits for respiratory
symptoms in the previous year (%)
48
Required antibiotics for chest infections in previous 3 months (%) 41
Required oral steroids for respiratory symptoms in previous
3 months (%)
37
Average FEV1 (% predicted) 36
FEV1- Forced Expiratory Volume in one second.compared to their wild type controls (~90% of WT).
However, following smoke exposure, each reached simi-
lar levels (~40% of WT). Hence, the presence of a pro-
tective 2nd normal CFTR allele was not sufficient to
overcome the functional decrement caused by smoke.
These data we provide the first experimental evidence
that acquired CFTR dysfunction from environmental ex-
posure to cigarette smoke or other COPD related path-
ology is the principle contributor to the defective ion
transport phenotype [15,19] and is not substantially af-
fected by the presence of CFTR mutation heterozygosity.
The degree of CFTR decrement observed following
smoke exposure and due to CFTR mutation heterozy-
gosity alone were each consistent with prior reports in
carriers [33], smokers [14,15], cells [17,30,36], and mice
[19] exposed to cigarette smoke and CF, lending further
confidence to our findings.
To confirm findings in the laboratory, we also investi-
gated whether genetic heterozygosity for CFTR muta-
tions contributes to the prevalence of COPD with
chronic bronchitis in cigarette smokers. We found that
CFTR mutations are not more frequent in COPD pa-
tients with moderate to severe obstruction and chronic
bronchitis symptoms compared to a control population
of Caucasian individuals. Despite clear evidence that
cigarette smoke reduces CFTR mediated anion trans-
port, these results suggest that congenital CFTR muta-
tions do not contribute to a genetic predisposition to the
prevalence of COPD and chronic bronchitis. Further,
our in vitro and in vivo data provide an explanation for
the absence of enhanced susceptibility to cigarette smoke
induced chronic bronchitis in individuals heterozygous for
CFTR mutations.
Unlike Gervais et al., we did not demonstrate an in-
creased association in the F508del CFTR allele and
chronic bronchitis, however this study observed the as-
sociation in individuals with elevated sweat chloride in
an era before comprehensive CFTR genetic analysis, po-
tentially resulting in the inclusion of patients with a mild
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mutations; smoking related COPD was also not specified
in this report [21]. Our findings also contrast to Kostuch
et al. who reported a slight increase (5 out of 32) in inci-
dence of F508del mutations in chronic bronchitis pa-
tients in Poland. Although the authors attempted to
enrich subjects for chronic bronchitis, the criterion used
in that study was based on persistent chronic effective
cough alone, and did not include any other clinical pa-
rameters such as a history of smoking. Similarly, we did
not observe any increase in the incidence of M470V or
R75Q as reported earlier in COPD patients from Serbia
[22,23]. These studies were based on small subject
groups (<20) and were based on limited clinical pheno-
typing. Further, the M470V polymorphism is no longer
thought to contribute to CF disease [39]. Differences in
the baseline prevalence of these less common CFTR muta-
tions due to genetic founder effects may also have contrib-
uted to the disparate results. Despite these distinctions,
the conclusion reported in this manuscript are based on a
more complete clinical evaluation and are in agreement
with conclusions drawn from large unbiased genetic ap-
proaches, including recent GWAS analyses, where no ap-
parent increase in CFTR mutations was observed [40].
The lack of an association with the prevalence of
chronic bronchitis stand in contrast to studies in asthma
where in a Swedish cohort of asthmatics, F508del CFTR
heterozygosity was significantly more prevalent when
compared to the control population. Further, asthmatic
individuals heterozygous for CFTR had decreased pul-
monary function and airway obstruction in comparison to
those without mutant CFTR alleles [41]. Similarly, CFTR
mutations have been reported in increased frequency
among patients with non-CF chronic rhinosinusitis [35].
This may be due to differences in the biology of COPD as
compared to these disorders, or the size of our study.
Our study has important limitations. Since, our ana-
lyses were focused on one sub-phenotype of COPD
(i.e. chronic bronchitis), it would be beneficial to con-
duct additional CFTR genetic analysis in a larger cohort of
subjects to rule out CFTR as a contributor. For example,
there are over 1900 potential disease-causing mutations in
CFTR [42] and our analysis was limited to the top 89.
Even though our analyses included 88% of alleles found in
Caucasians, CFTR sequencing may detect an association
not identified by our analyses. Furthermore, the same
principle could reduce the sensitivity of GWAS analyses
intended to detect an association with CFTR mutations,
since SNPs could be spread over many locations along the
CFTR gene, depending on the allele. Our study was per-
formed in a modest sized cohort and would be strength-
ened by a targeted approach in a much larger sample.
CFTR genetics could also influence the severity of the dis-
ease, rather than prevalence, and was not assessed by thisanalysis. While our animal studies recapitulated that ob-
served humans, they are not useful to evaluate chronic
bronchitis, since neither mice deficient in the CF gene or
chronically exposed to cigarette smoke develop mucus ob-
struction or retention. Larger animal models may be
needed for studies of this sort.
Conclusion
In total, the experimental data indicate why smokers with
CFTR mutations may not exhibit a genetic predisposition
to develop chronic bronchitis or a gene dose effect, even if
chronic bronchitis symptoms are partially mediated by ab-
normal CFTR function. Our data suggest that effects of
cigarette smoke on CFTR function acquired by environ-
mental exposure are far more influential to clinical pheno-
type than inherited defects due to mutations in CFTR.
These results may inform appropriate patient selection for
trials evaluating CFTR modulators or ion channel agonists
for the treatment of COPD [14,30].
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